NPIC
HAE icon

Neumeier Poma Investment Counsel’s Haemonetics HAE Stock Holding History

Neumeier Poma Investment Counsel’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-51,050
Closed -$2.15M – 41
2013
Q4 		$2.15M Sell
51,050
-104,175
-67% -$4.29M 0.49% 38
2013
Q3 		$6.19M Sell
155,225
-90,000
-37% -$3.78M 1.52% 32
2013
Q2 		$10.1M Buy
+245,225
New +$9.93M 2.65% 21

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Neumeier Poma Investment Counsel's HAE Position: Q1 2014 in Review

Neumeier Poma Investment Counsel sold out of Haemonetics (HAE) in Q1 2014, closing a stake of 51,050 shares — an estimated $2.15M sold.

Neumeier Poma Investment Counsel first reported a position in HAE in Q2 2013 and held it in 3 quarters. The position peaked at $10.1M in Q2 2013. 192 funds tracked by Wall St. Rank hold HAE as of Q1 2014.

  • Neumeier Poma Investment Counsel reported no remaining Haemonetics position as of Q1 2014 after selling out during the quarter.
  • Neumeier Poma Investment Counsel sold 51,050 Haemonetics shares in Q1 2014, an estimated $2.15M.
  • Neumeier Poma Investment Counsel first reported a position in Haemonetics in Q2 2013 and held it in 3 quarters.
  • Neumeier Poma Investment Counsel's Haemonetics position peaked at $10.1M in Q2 2013.
  • 192 funds tracked by Wall St. Rank held Haemonetics as of Q1 2014.

Based on Neumeier Poma Investment Counsel's 13F filing for Q1 2014, filed 14 May 2014.